Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Essential Therapeutics (ETRX) formerly Microcide (MCDE -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (351)	5/15/2001 4:08:35 PM
From: tuck	Read Replies (1) \| Respond to of 415

After the close: >>MOUNTAIN VIEW, Calif., May 15 /PRNewswire/ -- Microcide Pharmaceuticals, Inc. (Nasdaq: MCDE - news) today announced the successful completion of the funded preclinical research phase of its efflux pump inhibitor program with Daiichi Pharmaceutical Co., Ltd. (Tokyo, Japan). Microcide and Daiichi have been working together since 1995 in a program to discover and develop inhibitors able to overcome the effect of efflux pumps in Pseudomonas aeruginosa, a major cause of serious infections. Further preclinical and clinical work on candidate inhibitors will continue at Daiichi. Microcide will receive milestone payments and royalties on worldwide sales of any marketed products resulting from this research, and has retained product co-promotion rights for North America. ``In working together with Daiichi on the preclinical phases of this project, Microcide and Daiichi have made considerable progress in understanding the role of efflux pumps in bacteria,'' said Jim Rurka, President and CEO of Microcide. ``Efflux pumps eject antibiotics from bacteria, and thereby limit the effectiveness of current antibiotic therapies. Microcide and Daiichi have pioneered the development of efflux pump inhibitors which, when combined with an appropriate antibiotic, can potentiate its activity against both susceptible and resistant bacteria. If, as we believe, a fixed combination product of an anti-Pseudomonal antibiotic and an efflux pump inhibitor successfully emerges from this ongoing research, it will represent a new milestone in our efforts to overcome bacterial resistance.''<< snipped the boilerplate Cheers, Tuck